Ubiquitin- and proteasome-dependent pathway of protein degradation as an emerging therapeutic target

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The majority of cellular proteins are degraded by the ubiquitin-and proteasome-dependent proteolytic pathway. Among those proteins are various regulators of crucial processes, like the cell cycle, apoptosis, gene expression, angiogenesis, antigen presentation, inflammation etc. Therefore, the proteasome constitute an interesting target for drug discovery. Various inhibitors of this multicatalytic enzyme complex are already available. Experiments on animal models of various diseases have shown, that they can be useful anticancer, anti-inflammatory, anticachectic and antiparasital drugs. Clinical trials with at least one class of proteasome inhibitors are already conducted. The proteasome pathway is involved in the ethipathogenesis of some more groups of diseases, among them various neurodegenerative disorders. Proteasome activators and modulators can be of potential therapeutic use in these conditions.

Original languageEnglish (US)
Pages (from-to)89-111
Number of pages23
JournalExpert Opinion on Therapeutic Targets
Volume4
Issue number1
DOIs
StatePublished - Feb 1 2000
Externally publishedYes

Fingerprint

Proteasome Endopeptidase Complex
Ubiquitin
Proteolysis
Degradation
Proteins
Animal Disease Models
cdc Genes
Proteasome Inhibitors
Antigen Presentation
Enzyme Inhibitors
Therapeutic Uses
Drug Discovery
Therapeutics
Gene expression
Neurodegenerative Diseases
Modulators
Animals
Anti-Inflammatory Agents
Cells
Clinical Trials

Keywords

  • Alzheimer's disease
  • antigen presentation
  • cancer
  • drug discovery
  • hypertension
  • inflammation
  • malaria
  • neurodegeneration
  • proteasome
  • proteolysis
  • therapy
  • ubiquitin

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine

Cite this

@article{0257a2be13514a82a948ed4abd6b102b,
title = "Ubiquitin- and proteasome-dependent pathway of protein degradation as an emerging therapeutic target",
abstract = "The majority of cellular proteins are degraded by the ubiquitin-and proteasome-dependent proteolytic pathway. Among those proteins are various regulators of crucial processes, like the cell cycle, apoptosis, gene expression, angiogenesis, antigen presentation, inflammation etc. Therefore, the proteasome constitute an interesting target for drug discovery. Various inhibitors of this multicatalytic enzyme complex are already available. Experiments on animal models of various diseases have shown, that they can be useful anticancer, anti-inflammatory, anticachectic and antiparasital drugs. Clinical trials with at least one class of proteasome inhibitors are already conducted. The proteasome pathway is involved in the ethipathogenesis of some more groups of diseases, among them various neurodegenerative disorders. Proteasome activators and modulators can be of potential therapeutic use in these conditions.",
keywords = "Alzheimer's disease, antigen presentation, cancer, drug discovery, hypertension, inflammation, malaria, neurodegeneration, proteasome, proteolysis, therapy, ubiquitin",
author = "Cezary Wojcik",
year = "2000",
month = "2",
day = "1",
doi = "10.1517/14728222.4.1.89",
language = "English (US)",
volume = "4",
pages = "89--111",
journal = "Expert Opinion on Therapeutic Targets",
issn = "1472-8222",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Ubiquitin- and proteasome-dependent pathway of protein degradation as an emerging therapeutic target

AU - Wojcik, Cezary

PY - 2000/2/1

Y1 - 2000/2/1

N2 - The majority of cellular proteins are degraded by the ubiquitin-and proteasome-dependent proteolytic pathway. Among those proteins are various regulators of crucial processes, like the cell cycle, apoptosis, gene expression, angiogenesis, antigen presentation, inflammation etc. Therefore, the proteasome constitute an interesting target for drug discovery. Various inhibitors of this multicatalytic enzyme complex are already available. Experiments on animal models of various diseases have shown, that they can be useful anticancer, anti-inflammatory, anticachectic and antiparasital drugs. Clinical trials with at least one class of proteasome inhibitors are already conducted. The proteasome pathway is involved in the ethipathogenesis of some more groups of diseases, among them various neurodegenerative disorders. Proteasome activators and modulators can be of potential therapeutic use in these conditions.

AB - The majority of cellular proteins are degraded by the ubiquitin-and proteasome-dependent proteolytic pathway. Among those proteins are various regulators of crucial processes, like the cell cycle, apoptosis, gene expression, angiogenesis, antigen presentation, inflammation etc. Therefore, the proteasome constitute an interesting target for drug discovery. Various inhibitors of this multicatalytic enzyme complex are already available. Experiments on animal models of various diseases have shown, that they can be useful anticancer, anti-inflammatory, anticachectic and antiparasital drugs. Clinical trials with at least one class of proteasome inhibitors are already conducted. The proteasome pathway is involved in the ethipathogenesis of some more groups of diseases, among them various neurodegenerative disorders. Proteasome activators and modulators can be of potential therapeutic use in these conditions.

KW - Alzheimer's disease

KW - antigen presentation

KW - cancer

KW - drug discovery

KW - hypertension

KW - inflammation

KW - malaria

KW - neurodegeneration

KW - proteasome

KW - proteolysis

KW - therapy

KW - ubiquitin

UR - http://www.scopus.com/inward/record.url?scp=0002059613&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0002059613&partnerID=8YFLogxK

U2 - 10.1517/14728222.4.1.89

DO - 10.1517/14728222.4.1.89

M3 - Article

AN - SCOPUS:0002059613

VL - 4

SP - 89

EP - 111

JO - Expert Opinion on Therapeutic Targets

JF - Expert Opinion on Therapeutic Targets

SN - 1472-8222

IS - 1

ER -